Enhancement of the immune response to chronic myeloid leukaemia via controlled treatment scheduling
暂无分享,去创建一个
A. Astolfi | A. Astolfi | H. Chang | H. Chang
[1] Doron Levy,et al. Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. , 2005, Journal of theoretical biology.
[2] Frédéric Mazenc,et al. Stability of a Gleevec and immune model with delays , 2008, 2008 47th IEEE Conference on Decision and Control.
[3] Doron Levy,et al. Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia , 2008, PLoS Comput. Biol..
[4] Alessandro Astolfi,et al. Immune response’s enhancement via controlled drug scheduling , 2007, 2007 46th IEEE Conference on Decision and Control.
[5] B. Adams,et al. HIV dynamics: Modeling, data analysis, and optimal treatment protocols , 2005 .
[6] P. Klenerman,et al. Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysis. , 2001, Mathematical biosciences.
[7] C. Craddock,et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. , 2002, Blood.
[8] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[9] Holden T Maecker,et al. Development and dynamics of robust T-cell responses to CML under imatinib treatment. , 2008, Blood.
[10] Franziska Michor,et al. Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.
[11] Alessandro Astolfi,et al. Activation of Immune Response in Disease Dynamics via Controlled Drug Scheduling , 2009, IEEE Transactions on Automation Science and Engineering.
[12] Ryan Zurakowski,et al. A model predictive control based scheduling method for HIV therapy. , 2006, Journal of theoretical biology.
[13] Editors , 1986, Brain Research Bulletin.
[14] PCR , 1989, Cell.
[15] Silviu-Iulian Niculescu,et al. ON STABILITY OF A COMBINED GLEEVEC AND IMMUNE MODEL IN CHRONIC LEUKEMIA: EXPLOITING DELAY SYSTEM STRUCTURE , 2007 .
[16] F. Michor,et al. Reply: The long-term response to imatinib treatment of CML , 2007, British Journal of Cancer.